Literature DB >> 8828613

Studies of multimodal evoked potentials in treated phenylketonuria: the pattern of vulnerability.

A C Ludolph1, U Vetter, K Ullrich.   

Abstract

We performed studies of multimodal evoked potentials and peripheral sensory and motor nerve conductions in 33 early and 6 late treated patients with phenylketonuria. The studies revealed the following picture: 1. In 27% of early treated patients latencies of visual evoked potentials were increased. The cause for these changes in unknown. 2. Nerve conduction studies showed the presence of a minor sensory neuropathy which in rare cases may also affect peripheral motor nerves. This neuropathy did not have features of a central-peripheral distal axonopathy which argues against a toxic/nutritional causation. 3. Deficits in the central sensory, motor, and auditory pathways were present, but rare in early treated patients. If the results of electrophysiological studies reported by different groups are compared, the emerging picture is very similar and the majority of the-minor-differences is likely to be explained by technical aspects.

Entities:  

Mesh:

Year:  1996        PMID: 8828613     DOI: 10.1007/pl00014254

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  16 in total

1.  Neurological outcome in 22 treated adolescents with hyperphenylalaninemia. A clinical and electrophysiological study.

Authors:  A C Ludolph; K Ullrich; S Nedjat; H Masur; U Bick
Journal:  Acta Neurol Scand       Date:  1992-04       Impact factor: 3.209

2.  Magnetic resonance imaging changes in early treated patients with phenylketonuria.

Authors:  A J Thompson; I Smith; B E Kendall; B D Youl; D Brenton
Journal:  Lancet       Date:  1991-05-18       Impact factor: 79.321

3.  Deficits in selective and sustained attention processes in early treated children with phenylketonuria--result of impaired frontal lobe functions?

Authors:  J Weglage; M Pietsch; B Funders; H G Koch; K Ullrich
Journal:  Eur J Pediatr       Date:  1996-03       Impact factor: 3.183

4.  Neurophysiological studies of patients with classical phenylketonuria: evaluation of results of IQ scores, EEG and evoked potentials.

Authors:  T Coşkun; M Topçu; I Ustündağ; I Ozalp; Y Renda; A Ciğer; G Nurlu
Journal:  Turk J Pediatr       Date:  1993 Jan-Mar       Impact factor: 0.552

5.  The development of auditory and visual evoked potentials in early treated phenylketonuric children.

Authors:  F Cardona; V Leuzzi; I Antonozzi; P Benedetti; A Loizzo
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1991 Jan-Feb

6.  Evoked potentials and electroencephalography in adolescents with phenylketonuria.

Authors:  R Korinthenberg; K Ullrich; F Füllenkemper
Journal:  Neuropediatrics       Date:  1988-11       Impact factor: 1.947

7.  Neurological deterioration in adult phenylketonuria.

Authors:  D Villasana; I J Butler; J C Williams; S M Roongta
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

8.  Vitamin B12 deficiency in adolescents and young adults with phenylketonuria.

Authors:  W B Hanley; A S Feigenbaum; J T Clarke; W E Schoonheyt; V J Austin
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

9.  EEGs in phenylketonuria. I: Follow-up to adulthood; II: Short-term diet-related changes in EEGs and cognitive function.

Authors:  J Pietz; E Schmidt; P Matthis; B Kobialka; A Kutscha; L de Sonneville
Journal:  Dev Med Child Neurol       Date:  1993-01       Impact factor: 5.449

10.  Magnetic resonance imaging of the brain in phenylketonuria.

Authors:  M A Cleary; J H Walter; J E Wraith; J P Jenkins; S M Alani; K Tyler; D Whittle
Journal:  Lancet       Date:  1994-07-09       Impact factor: 79.321

View more
  1 in total

1.  Subclinical visual impairment in phenylketonuria. A neurophysiological study (VEP-P) with clinical, biochemical, and neuroradiological (MRI) correlations.

Authors:  V Leuzzi; S Rinalduzzi; F Chiarotti; P Garzia; G Trasimeni; N Accornero
Journal:  J Inherit Metab Dis       Date:  1998-06       Impact factor: 4.982

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.